Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease
Paolo Rossato, Helmut Glantschnig, Fabio Canneva, Maria Schuster, Sogué Coulibaly, Gerald Schrenk, Dirk Voelkel, Michael Dockal, Barbara Plaimauer, Hanspeter Rottensteiner, Herbert Gritsch, Enrica Federti, Alessandro Mattè, Lucia De Franceschi, Friedrich Scheiflinger, Werner Hoellriegl
Topics & Concepts
ADAMTS13Von Willebrand factorMedicineImmunologyHypoxia (environmental)InflammationHemolysisSickle cell anemiaHemoglobinPharmacologyInternal medicinePlateletDiseaseChemistryOxygenOrganic chemistryComplement system in diseasesHemoglobinopathies and Related DisordersBlood groups and transfusion